{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T23:17:52Z","timestamp":1791328672385,"version":"4.3.1"},"reference-count":44,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2010,8,1]],"date-time":"2010-08-01T00:00:00Z","timestamp":1280620800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Diagnostic Microbiology and Infectious Disease"],"published-print":{"date-parts":[[2010,8]]},"DOI":"10.1016\/j.diagmicrobio.2010.03.009","type":"journal-article","created":{"date-parts":[[2010,7,17]],"date-time":"2010-07-17T08:49:54Z","timestamp":1279356594000},"page":"359-368","source":"Crossref","is-referenced-by-count":32,"title":["Worldwide summary of telavancin spectrum and potency against Gram-positive pathogens: 2007 to 2008 surveillance results"],"prefix":"10.1016","volume":"67","author":[{"given":"Shannon D.","family":"Putnam","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helio S.","family":"Sader","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary J.","family":"Moet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodrigo E.","family":"Mendes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald N.","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.diagmicrobio.2010.03.009_bib1","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1093\/jac\/dkl424","article-title":"Evaluation of the extracellular and intracellular activities (human THP-1 macrophages) of telavancin versus vancomycin against methicillin-susceptible, methicillin-resistant, vancomycin-intermediate and vancomycin-resistant Staphylococcus aureus","volume":"58","author":"Barcia-Macay","year":"2006","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.diagmicrobio.2010.03.009_bib2","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1177\/0091270004266620","article-title":"Effects of a new antibacterial, telavancin, on cardiac repolarization (QTc interval duration) in healthy subjects","volume":"44","author":"Barriere","year":"2004","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.diagmicrobio.2010.03.009_bib3","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1086\/597521","article-title":"Pediatric and neonatal Staphylococcus aureus bacteremia: epidemiology, risk factors, and outcome","volume":"30","author":"Burke","year":"2009","journal-title":"Infect. Control Hosp. Epidemiol."},{"key":"10.1016\/j.diagmicrobio.2010.03.009_bib4","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1345\/aph.1G417","article-title":"Telavancin: a novel lipoglycopeptide antibiotic","volume":"43","author":"Charneski","year":"2009","journal-title":"Ann. Pharmacother."},{"key":"10.1016\/j.diagmicrobio.2010.03.009_bib5","series-title":"Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard\u2014eighth edition, M07-A8","author":"Clinical and Laboratory Standards Institute (CLSI)","year":"2009"},{"key":"10.1016\/j.diagmicrobio.2010.03.009_bib6","series-title":"Performance standards for antimicrobial susceptibility testing: 20th informational supplement (M100-S20)","author":"Clinical and Laboratory Standards Institute (CLSI)","year":"2010"},{"key":"10.1016\/j.diagmicrobio.2010.03.009_bib7","doi-asserted-by":"crossref","first-page":"2626","DOI":"10.1128\/AAC.01101-08","article-title":"Comparative efficacies of telavancin and vancomycin in preventing device-associated colonization and infection by Staphylococcus aureus in rabbits","volume":"53","author":"Darouiche","year":"2009","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.diagmicrobio.2010.03.009_bib8","doi-asserted-by":"crossref","first-page":"2383","DOI":"10.1128\/AAC.01641-07","article-title":"Comparative surveillance study of telavancin activity against recently collected gram-positive clinical isolates from across the United States","volume":"52","author":"Draghi","year":"2008","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.diagmicrobio.2010.03.009_bib9","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1093\/jac\/dkn124","article-title":"In vitro activity of telavancin against recent Gram-positive clinical isolates: results of the 2004\u201305 Prospective European Surveillance Initiative","volume":"62","author":"Draghi","year":"2008","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.diagmicrobio.2010.03.009_bib10","doi-asserted-by":"crossref","first-page":"235","DOI":"10.2147\/TCRM.S1843","article-title":"A review of telavancin in the treatment of complicated skin and skin structure infections (cSSSI)","volume":"4","author":"Dunbar","year":"2008","journal-title":"Ther. Clin. Risk Manag."},{"key":"10.1016\/j.diagmicrobio.2010.03.009_bib11","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1007\/s10096-009-0741-5","article-title":"Clinical features and treatment outcomes of vancomycin-intermediate Staphylococcus aureus (VISA) and heteroresistant vancomycin-intermediate Staphylococcus aureus (hVISA) in a tertiary care institution in Singapore","volume":"28","author":"Fong","year":"2009","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"10.1016\/j.diagmicrobio.2010.03.009_bib12","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1093\/jac\/dki198","article-title":"Telavancin: in vitro activity against staphylococci in a biofilm model","volume":"56","author":"Gander","year":"2005","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.diagmicrobio.2010.03.009_bib13","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.1128\/AAC.48.6.2149-2152.2004","article-title":"In vitro activities of the new semisynthetic glycopeptide telavancin (TD-6424), vancomycin, daptomycin, linezolid, and four comparator agents against anaerobic Gram-positive species and Corynebacterium spp","volume":"48","author":"Goldstein","year":"2004","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.diagmicrobio.2010.03.009_bib14","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1093\/jac\/dkp001","article-title":"Efficacy of telavancin against glycopeptide-intermediate Staphylococcus aureus in the neutropenic mouse bacteraemia model","volume":"63","author":"Hegde","year":"2009","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.diagmicrobio.2010.03.009_bib15","doi-asserted-by":"crossref","first-page":"3043","DOI":"10.1128\/AAC.48.8.3043-3050.2004","article-title":"Pharmacodynamics of telavancin (TD-6424), a novel bactericidal agent, against Gram-positive bacteria","volume":"48","author":"Hegde","year":"2004","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.diagmicrobio.2010.03.009_bib16","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1128\/AAC.49.3.1127-1134.2005","article-title":"Telavancin, a multifunctional lipoglycopeptide, disrupts both cell wall synthesis and cell membrane integrity in methicillin-resistant Staphylococcus aureus","volume":"49","author":"Higgins","year":"2005","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.diagmicrobio.2010.03.009_bib17","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1177\/0310057X0903700320","article-title":"Risk factors and outcomes of methicillin-resistant Staphylococcus aureus bacteraemia in critically ill patients: a case control study","volume":"37","author":"Ho","year":"2009","journal-title":"Anaesth. Intensive Care"},{"key":"10.1016\/j.diagmicrobio.2010.03.009_bib18","doi-asserted-by":"crossref","first-page":"3420","DOI":"10.1128\/AAC.00100-07","article-title":"In vitro activity of telavancin against gram-positive clinical isolates recently obtained in Europe","volume":"51","author":"Jansen","year":"2007","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.diagmicrobio.2010.03.009_bib19","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1093\/jac\/dkh156","article-title":"Comparative in vitro activity of telavancin (TD-6424), a rapidly bactericidal, concentration-dependent anti-infective with multiple mechanisms of action against Gram-positive bacteria","volume":"53","author":"King","year":"2004","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.diagmicrobio.2010.03.009_bib20","doi-asserted-by":"crossref","first-page":"2647","DOI":"10.1128\/AAC.01398-07","article-title":"In vitro activity of telavancin against resistant gram-positive bacteria","volume":"52","author":"Krause","year":"2008","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.diagmicrobio.2010.03.009_bib21","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1093\/jac\/dkn439","article-title":"Evaluation of vancomycin and daptomycin against methicillin-resistant Staphylococcus aureus and heterogeneously vancomycin-intermediate S. aureus in an in vitro pharmacokinetic\/pharmacodynamic model with simulated endocardial vegetations","volume":"63","author":"Leonard","year":"2009","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.diagmicrobio.2010.03.009_bib22","doi-asserted-by":"crossref","first-page":"2928","DOI":"10.1128\/AAC.01544-08","article-title":"Activity of telavancin against Staphylococcus aureus of varying vancomycin susceptibilities in an in vitro pharmacokinetic\/pharmacodynamic model with simulated endocardial vegetations","volume":"53","author":"Leonard","year":"2009","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.diagmicrobio.2010.03.009_bib23","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1093\/jac\/dkl235","article-title":"Comparative activity of the new lipoglycopeptide telavancin in the presence and absence of serum against 50 glycopeptide non-susceptible staphylococci and three vancomycin-resistant Staphylococcus aureus","volume":"58","author":"Leuthner","year":"2006","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.diagmicrobio.2010.03.009_bib24","doi-asserted-by":"crossref","first-page":"2300","DOI":"10.1128\/AAC.01110-07","article-title":"Telavancin penetration into human epithelial lining fluid determined by population pharmacokinetic modeling and Monte Carlo simulation","volume":"52","author":"Lodise","year":"2008","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.diagmicrobio.2010.03.009_bib25","doi-asserted-by":"crossref","first-page":"3375","DOI":"10.1128\/AAC.01710-08","article-title":"Telavancin disrupts the functional integrity of the bacterial membrane through targeted Interaction with the cell wall precursor lipid II","volume":"53","author":"Lunde","year":"2009","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.diagmicrobio.2010.03.009_bib26","doi-asserted-by":"crossref","first-page":"3163","DOI":"10.1128\/AAC.49.8.3163-3165.2005","article-title":"Efficacy of telavancin in a rabbit model of aortic valve endocarditis due to methicillin-resistant Staphylococcus aureus or vancomycin-intermediate Staphylococcus aureus","volume":"49","author":"Madrigal","year":"2005","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.diagmicrobio.2010.03.009_bib27","doi-asserted-by":"crossref","first-page":"2373","DOI":"10.1128\/AAC.01266-06","article-title":"Efficacy of telavancin in the treatment of experimental endocarditis due to glycopeptide-intermediate Staphylococcus aureus","volume":"51","author":"Miro","year":"2007","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.diagmicrobio.2010.03.009_bib28","doi-asserted-by":"crossref","first-page":"3311","DOI":"10.1128\/AAC.01470-06","article-title":"Pharmacodynamic effects of telavancin against methicillin-resistant and methicillin-susceptible Staphylococcus aureus strains in the presence of human albumin or serum and in an in vitro kinetic model","volume":"51","author":"Odenholt","year":"2007","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.diagmicrobio.2010.03.009_bib29","first-page":"216","article-title":"Telavancin (Theravance)","volume":"6","author":"Pace","year":"2005","journal-title":"Curr. Opin. Invest. Drugs"},{"key":"10.1016\/j.diagmicrobio.2010.03.009_bib30","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1093\/jac\/dkl222","article-title":"Efficacy of telavancin in a murine model of bacteraemia induced by methicillin-resistant Staphylococcus aureus","volume":"58","author":"Reyes","year":"2006","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.diagmicrobio.2010.03.009_bib31","doi-asserted-by":"crossref","first-page":"4344","DOI":"10.1128\/AAC.49.10.4344-4346.2005","article-title":"Efficacy of telavancin (TD-6424), a rapidly bactericidal lipoglycopeptide with multiple mechanisms of action, in a murine model of pneumonia induced by methicillin-resistant Staphylococcus aureus","volume":"49","author":"Reyes","year":"2005","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.diagmicrobio.2010.03.009_bib32","series-title":"In: 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy","first-page":"454","article-title":"Telavancin for the treatment of hospital-acquired pneumonia in severely ill and older patients: the ATTAIN studies","author":"Rubinstein","year":"2008"},{"key":"10.1016\/j.diagmicrobio.2010.03.009_bib33","series-title":"Abstracts of the Forty-eighth Interscience Conference on Antimicrobial Agents and Chemotherapy","first-page":"454","article-title":"Telavancin for the treatment of hospital-acquired pneumonia caused by MRSA and MSSA: the ATTAIN studies. In: 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy","author":"Rubinstein","year":"2008"},{"key":"10.1016\/j.diagmicrobio.2010.03.009_bib34","doi-asserted-by":"crossref","first-page":"1908","DOI":"10.1086\/648438","article-title":"Telavancin: a novel lipoglycopeptide","volume":"49","author":"Saravolatz","year":"2009","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.diagmicrobio.2010.03.009_bib35","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1128\/AAC.49.1.195-201.2005","article-title":"Pharmacokinetics, serum inhibitory and bactericidal activity, and safety of telavancin in healthy subjects","volume":"49","author":"Shaw","year":"2005","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.diagmicrobio.2010.03.009_bib36","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1128\/AAC.50.3.862-867.2006","article-title":"Telavancin versus standard therapy for treatment of complicated skin and skin structure infections caused by Gram-positive bacteria: FAST 2 study","volume":"50","author":"Stryjewski","year":"2006","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.diagmicrobio.2010.03.009_bib37","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1086\/587896","article-title":"Telavancin versus vancomycin for the treatment of complicated skin and skin-structure infections caused by gram-positive organisms","volume":"46","author":"Stryjewski","year":"2008","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.diagmicrobio.2010.03.009_bib38","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1086\/429914","article-title":"Telavancin versus standard therapy for treatment of complicated skin and soft-tissue infections due to Gram-positive bacteria","volume":"40","author":"Stryjewski","year":"2005","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.diagmicrobio.2010.03.009_bib39","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1128\/AAC.50.2.770-773.2006","article-title":"Efficacy of telavancin against penicillin-resistant pneumococci and Staphylococcus aureus in a rabbit meningitis model and determination of kinetic parameters","volume":"50","author":"Stucki","year":"2006","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.diagmicrobio.2010.03.009_bib40","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1128\/AAC.50.2.788-790.2006","article-title":"Tissue penetration of telavancin after intravenous administration in healthy subjects","volume":"50","author":"Sun","year":"2006","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.diagmicrobio.2010.03.009_bib41","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.diagmicrobio.2007.11.011","article-title":"Evaluation of daptomycin, telavancin, teicoplanin, and vancomycin activity in the presence of albumin or serum","volume":"60","author":"Tsuji","year":"2008","journal-title":"Diagn. Microbiol. Infect. Dis."},{"key":"10.1016\/j.diagmicrobio.2010.03.009_bib42","unstructured":"VIBATIV\u2122 (Package Insert), Astellas Pharma US, Inc., Deerfield, IL and Theravance, Inc. South San Francisco, CA. Available at: http:\/\/www.vibativ.com. Accessed January 28, 2010."},{"key":"10.1016\/j.diagmicrobio.2010.03.009_bib43","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/j.amjsurg.2008.05.012","article-title":"Telavancin versus vancomycin for the treatment of complicated skin and skin-structure infections associated with surgical procedures","volume":"197","author":"Wilson","year":"2009","journal-title":"Am. J. Surg."},{"key":"10.1016\/j.diagmicrobio.2010.03.009_bib44","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1093\/jac\/dkn490","article-title":"Efficacy of telavancin in the treatment of methicillin-resistant Staphylococcus aureus osteomyelitis: studies with a rabbit model","volume":"63","author":"Yin","year":"2009","journal-title":"J. Antimicrob. Chemother."}],"container-title":["Diagnostic Microbiology and Infectious Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S073288931000115X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S073288931000115X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,5,31]],"date-time":"2019-05-31T06:04:20Z","timestamp":1559282660000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S073288931000115X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,8]]},"references-count":44,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2010,8]]}},"alternative-id":["S073288931000115X"],"URL":"https:\/\/doi.org\/10.1016\/j.diagmicrobio.2010.03.009","relation":{},"ISSN":["0732-8893"],"issn-type":[{"value":"0732-8893","type":"print"}],"subject":[],"published":{"date-parts":[[2010,8]]}}}